Skip to main content
Equibles
ORMP logo

ORMP · Oramed Pharmaceuticals Inc.

Track ORMP — free

Use ORMP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ORMP

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.78 -0.01 (-0.21%) At close · Aug 21
Market Cap
$200.08M
Shares
41.60M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.79 Open$4.78 Day$4.68–4.86 52W close$2.06–5.00 Avg vol 30d180K Short int835K · 2.0% float · 5.7d Short vol48% DataJan 2020–Aug 2026 Filing10-Q · Aug 10

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16 · calm Equity put/call 0.58
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +33%
above
Price vs 50-day avg +13%
above
RSI (14) 69
neutral
MACD trend Positive
52-week position 93%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +15%
trailing
6-month return +40%
trailing
YTD return +68%
this year
Relative strength +29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+31% holders QoQ · +29 funds added
Insider flow Distributing
Net -$942.2K over 90 days · 100% sells
Short interest Rising
2.01% of float · ▲ +9.2% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
84 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Strong
Revenue growth +49%
Y/Y
Gross margin 1%
EPS growth +413%
Y/Y
Free cash flow $-9.2M
Valuation P/E 1.2
below peers
Buyback $469.0K
authorized
Balance sheet $5.1M
net debt
Quant / Vol
risk profile
Very High
Volatility 55%
annualized · 1-yr
Max drawdown −24%
past year
ATR 4.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+33% Bullish
Price vs 50-day avg
+13% Bullish
RSI (14)
69 Neutral
MACD trend
Positive Bullish
52-week position
93% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+31% holders QoQ · +29 funds added
Insider flow Distributing
Net -$942.2K over 90 days · 100% sells
Short interest Rising
2.01% of float · ▲ +9.2% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
84 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $5 · 93% Range high $5
vs 200-day avg +33% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ORMP
Oramed Pharmaceuticals Inc.
this stock
$200.08M +68.1% — 1.2 2.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
ARGX
Argenx SE
 $64.56B +23.4% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
84
% held
40.4%
Net QoQ
+3.6M sh
Top holder
MERCER GLOBAL ADVISORS IN…
Held Float
View
Held by Funds
Fund positions
24
View
Short & Settlement
Short Interest Rising
Shares short
835.5K
Days to cover
5.7d
Change
+70.1K sh
View
Short Volume
Short vol %
48%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$4.5K
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
42.2%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$942.2K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Congressional Trades Sell
Member
Brad Knott
Amount
$15.0K–$50.0K
Traded
Jan 10, 2025
View
Financials
Financials
Revenue (FY)
$2.0M
Net income (FY)
$64.1M
EPS diluted
$1.50
View
Buybacks
Authorized
$469.0K
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 10, 2026
This year
9
View
Proposed Sales
Value
$449.1K
Shares
93.4K
Filed
Jul 1, 2026
View

Performance

5D 20D 120D MTD YTD
ORMP +9.4% +15.1% +40.1% +17.7% +68.1%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +11.3% +11.8% +28.9% +15.6% +56.2%

Capital returns

Latest dividend
$0.25 / share · ex Jan 16, 2026
Paid (TTM)
$0.25 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Buyback program · as of Mar 31, 2026
Authorized
$469,000
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1176309 CUSIP 68403P203 13F (30d) 80 filings 79 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)